174 related articles for article (PubMed ID: 34148794)
1. Korean clinical practice guideline for pancreatic cancer 2021: A summary of evidence-based, multi-disciplinary diagnostic and therapeutic approaches.
Committee of the Korean clinical practice guideline for pancreatic cancer and National Cancer Center, Korea
Pancreatology; 2021 Oct; 21(7):1326-1341. PubMed ID: 34148794
[TBL] [Abstract][Full Text] [Related]
2. Korean Surgical Practice Guideline for Pancreatic Cancer 2022: A summary of evidence-based surgical approaches.
Lee SE; Han SS; Kang CM; Kwon W; Paik KY; Song KB; Yang JD; Chung JC; Jeong CY; Kim SW;
Ann Hepatobiliary Pancreat Surg; 2022 Feb; 26(1):1-16. PubMed ID: 35220285
[TBL] [Abstract][Full Text] [Related]
3. Evolving pancreatic cancer treatment: From diagnosis to healthcare management.
Milella M; Bassi C; Boggi U; Brunetti O; Cavaliere A; Crippa S; De Vita F; Falconi M; Frassineti GL; Giommoni E; Macchini M; Malleo G; Silvestris N; Tudisco A; Vasile E; Reni M
Crit Rev Oncol Hematol; 2022 Jan; 169():103571. PubMed ID: 34923121
[TBL] [Abstract][Full Text] [Related]
4. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
[TBL] [Abstract][Full Text] [Related]
5. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis.
Okusaka T; Nakamura M; Yoshida M; Kitano M; Ito Y; Mizuno N; Hanada K; Ozaka M; Morizane C; Takeyama Y;
Int J Clin Oncol; 2023 Apr; 28(4):493-511. PubMed ID: 36920680
[TBL] [Abstract][Full Text] [Related]
6. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic cancer: An update on diagnosis and management.
Loveday BPT; Lipton L; Thomson BN
Aust J Gen Pract; 2019 Dec; 48(12):826-831. PubMed ID: 31774983
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant treatment of surgically resectable pancreatic ductal adenocarcinoma.
Tesfaye AA; Philip PA
Clin Adv Hematol Oncol; 2019 Jan; 17(1):54-63. PubMed ID: 30843899
[TBL] [Abstract][Full Text] [Related]
9. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.
;
Gut Liver; 2019 May; 13(3):227-299. PubMed ID: 31060120
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma.
Silvestris N; Longo V; Cellini F; Reni M; Bittoni A; Cataldo I; Partelli S; Falconi M; Scarpa A; Brunetti O; Lorusso V; Santini D; Morganti A; Valentini V; Cascinu S
Crit Rev Oncol Hematol; 2016 Feb; 98():309-24. PubMed ID: 26653573
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant therapy for pancreatic cancer.
Gugenheim J; Crovetto A; Petrucciani N
Updates Surg; 2022 Feb; 74(1):35-42. PubMed ID: 34628591
[TBL] [Abstract][Full Text] [Related]
12. The treatment of locally advanced pancreatic cancer: a practice guideline.
Earle CC; Agboola O; Maroun J; Zuraw L;
Can J Gastroenterol; 2003 Mar; 17(3):161-7. PubMed ID: 12677264
[TBL] [Abstract][Full Text] [Related]
13. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
[TBL] [Abstract][Full Text] [Related]
14. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Balaban EP; Mangu PB; Khorana AA; Shah MA; Mukherjee S; Crane CH; Javle MM; Eads JR; Allen P; Ko AH; Engebretson A; Herman JM; Strickler JH; Benson AB; Urba S; Yee NS
J Clin Oncol; 2016 Aug; 34(22):2654-68. PubMed ID: 27247216
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma.
Álvarez R; Alés I; Díaz R; de Paredes BG; Hidalgo M
Clin Transl Oncol; 2017 Oct; 19(10):1193-1198. PubMed ID: 28612203
[TBL] [Abstract][Full Text] [Related]
16. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S
Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257
[TBL] [Abstract][Full Text] [Related]
17. [The guideline for neoadjuvant therapy of pancreatic cancer in China (2020 edition)].
;
Zhonghua Wai Ke Za Zhi; 2020 Sep; 58(9):657-667. PubMed ID: 32878410
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and Management of Borderline Resectable Pancreatic Adenocarcinoma.
Schwarz L; Katz MH
Hematol Oncol Clin North Am; 2015 Aug; 29(4):727-40. PubMed ID: 26226907
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Chemotherapy in Pancreatic Cancer: An Appraisal of the Current High-Level Evidence.
Müller PC; Frey MC; Ruzza CM; Nickel F; Jost C; Gwerder C; Hackert T; Z'graggen K; Kessler U
Pharmacology; 2021; 106(3-4):143-153. PubMed ID: 32966993
[TBL] [Abstract][Full Text] [Related]
20. Endoscopic ultrasound (EUS) and the management of pancreatic cancer.
Yousaf MN; Chaudhary FS; Ehsan A; Suarez AL; Muniraj T; Jamidar P; Aslanian HR; Farrell JJ
BMJ Open Gastroenterol; 2020 May; 7(1):. PubMed ID: 32414753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
